

BOSTON SCIENTIFIC ANNOUNCES FIRST EUROPEAN IMPLANT OF NEW FAMILY OF ADVANCED PACEMAKERS

Paris, France (May 14, 2008) -- Boston Scientific Corporation (NYSE: BSX) today announced the first European implant of its ALTRUA™ family of pacemakers, which recently received CE Mark approval. The procedure was performed by Dr. Mark Hall at The Cardiothoracic Centre, Liverpool, NHS Trust, United Kingdom.

ALTRUA™ is Boston Scientific's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the first Boston Scientific-branded pacemaker to treat bradycardia, a condition in which the heart beats too slowly -- usually less than 60 beats per minute -- depriving the body of sufficient oxygen.

"The ALTRUA pacemaker is very easy to use even with its advanced diagnostics," said Dr. Hall. "The one-button programmability of the ALTRUA pacemaker enables me to spend more time with my patients and less time programming device features."

The ALTRUA pacemaker provides physicians with a number of diagnostic and therapeutic capabilities that enable them to tailor the therapy to specific patient requirements:

- **Multiple Atrial Ventricular (AV) Delay programming options:** These options are designed to reduce unnecessary right ventricular (RV) pacing, without dropping ventricular beats, a key distinction from other competitive RV pacing algorithms. The ALTRUA 50 and 60 series also include an enhanced AV search hysteresis feature, now with an extendable AV delay out to 400 milliseconds, providing physicians with additional flexibility to tailor device programming for unique patient needs.
- **Minute Ventilation (MV) Blended Sensor:** MV with Auto Lifestyle treats a condition called Chronotropic Incompetence, which is the inability of the heart to regulate its rate appropriately in response to physical activity and emotional stress.
- **Ventricular Rate Regulation (VRR):** This therapy, alone or in combination with other atrial fibrillation (AF) treating algorithms, stabilizes the patient's heart rhythm and reduces AF symptoms.
- **Automatic Capture:** This capability is designed to offer automatic, safe and accurate ventricular pulse management. The device checks every heart beat to see if the lower

chambers of the heart contract in response to the delivered pulse. If no contraction is detected, a backup pace with more energy is delivered.

“European approval and launch of Boston Scientific’s ALTRUA family of pacemakers is the latest example of the significant progress we have made rebuilding our CRM organization and reinvigorating our product pipeline,” said Fred Colen, Executive Vice President, Operations and Technology, CRM. “ALTRUA’s innovative technology -- enabling physicians to adjust the therapy to meet the needs of their patients -- demonstrates our renewed focus on treating bradycardia.”

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific-international.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, regulatory approval of our products, new product launches, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Géraldine Varoqui
Boston Scientific PR Manager International
Tel: +49 2102 489 461
varoqui@bsci.com

OR

Tracy Paul
BSC press office
Tel: + 44 20 7413 3101
tpaul@medicalknowledgegroup.com